What Dolalgial Treats: Main Uses and Benefits

The therapeutic utility of Clonixin Lysinate (Dolalgial) is associated with symptoms related to inflammatory or irritative states. The compound is utilized in areas where short-term symptomatic assistance is needed in situations involving certain distressing symptoms.

Therapeutic Scope and Benefits

Clonixin Lysinate is commonly used across conditions presenting with acute episodes characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive in conditions such as severe headaches (including migraine attacks), the acute pain of renal colic, and discomfort related to muscular or joint injuries. Furthermore, it is commonly used to help with symptoms related to recurrent or episodic manifestations, such as menstrual pain (dysmenorrhea) and discomfort following dental or surgical procedures. This medication provides support that helps ease the overall symptom burden during symptomatic periods.

“Applied in scenarios where additional management of discomfort is required, the medication may assist patients with maintaining functional stability.”

Quick Fact: Supportive Role in Acute Discomfort
Focus Area	Symptomatic relief for moderate to moderately severe pain and associated localized swelling.
Target Contexts	Episodic pain, post-procedural discomfort, and inflammatory states.

Dolalgial's active ingredient, Tramadol, is an opioid medication and is subject to strict eligibility rules defined in regulatory labeling. Its use is generally reserved for adult patients (18 years and older) when non-opioid pain treatments have failed or are not tolerated, due to risks including addiction, abuse, and respiratory depression.

Contraindicated Populations

Use is prohibited for:

• Children under 12 years of age.
• Children under 18 years of age for postoperative pain following tonsillectomy or adenoidectomy.
• Individuals with significant respiratory depression, acute or severe asthma (in an unmonitored setting), or known or suspected gastrointestinal obstruction (e.g., paralytic ileus).
• Those with known hypersensitivity to tramadol or other opioids.

Restricted or Not Recommended Use

• Breastfeeding is not recommended.
• Patients with severe renal or hepatic impairment require dose reductions and extended dosing intervals; the maximum daily dose is limited.
• Caution is necessary for patients with a history of seizures or those considered suicidal or addiction-prone.

Dolalgial Interactions with other medicines and products

This section outlines the officially documented interaction profile of Dolalgial (Clonixin Lysinate), based strictly on government regulatory sources and the established Nonsteroidal Anti-inflammatory Drug (NSAID) class effects.

Documented High-Risk Combinations

Regulatory labels often categorize certain combinations as high-risk due to amplified adverse effects:

• Other NSAIDs (including COX-2 inhibitors) and High-dose Salicylates (e.g., Aspirin): Co-administration is generally restricted due to a significantly increased risk of serious gastrointestinal bleeding and kidney impairment.

Interactions Affecting Drug Exposure and Bleeding Risk

Co-administration with Dolalgial can alter the effects of the following medicines, as noted in official prescribing information:

Interacting Substance Category	Officially Documented Effect	Constraint Type
Anticoagulants (e.g., Warfarin) & Antiplatelet Agents	Increased risk of bleeding and hemorrhage (Additive pharmacodynamic effect)	Requires Caution
Methotrexate & Lithium	Increased plasma concentrations and toxicity (Reduced renal clearance)	Requires Monitoring
Antihypertensives (e.g., ACE Inhibitors, Diuretics)	Potential for reduced effectiveness of the blood pressure medicine	Requires Caution
SSRIs/SNRIs	Increased risk of gastrointestinal bleeding (Pharmacodynamic effect)	Requires Caution

Official regulatory cautions state that the risk and severity of these interactions are higher in elderly patients and individuals with pre-existing renal impairment.

Inhibition of Dual Inflammatory Pathways

Clonixin Lysinate's primary mechanism involves the non-selective inhibition of both the Cyclooxygenase (COX) enzymes and, uniquely, the 5-Lipoxygenase (5-LOX) enzyme. This dual molecular blockade stops the body from synthesizing the major chemical mediators—Prostaglandins and Leukotrienes—that mediate inflammation and nociceptive signaling, leading to the suppression of inflammatory pathway activity.

Modulation of Nociceptive Signaling

The molecular effect of reduced Prostaglandin E2 prevents the amplification of signals from peripheral nociceptors (pain-sensing nerve endings), limiting the generation of pain messages. This is supplemented by a distinct action on cellular calcium currents that results in the reduction of excitability within nociceptive cells, which contributes to the modulation of peripheral signal transmission.

Suppression of Thermoregulatory Processes

The drug's mechanism also extends centrally, where the suppression of PGE2 production specifically in the hypothalamus—the brain region governing body temperature—modifies the body’s thermal set-point. This modification engages a homeostatic mechanism that influences the body's internal thermal set-point, resulting in the physiological adjustment of elevated body temperature.

Dolalgial, which contains the active compound Clonixin Lysinate, is associated with specific administration patterns. The medication is supplied in formulations for both oral ingestion (as tablets or solution) and Intravenous (IV) injection. This dual availability allows for different administrative approaches based on the clinical setting.

Official Administration Protocol

Standard administration involves clear parameters for both dose and frequency. The oral adult dose typically ranges from 125 mg to 300 mg per administration. These oral doses are typically separated by a consistent time interval, commonly every 8 hours, to maintain a scheduled pattern. The intravenous dose, generally presented as 200 mg per use, is reserved for situations requiring a higher degree of clinical control.

Use Context and Duration

Intravenous administration is a procedural requirement indicating its use within a supervised healthcare environment for acute situations. The overall duration of therapy is constrained to a short-term course, generally lasting 7 to 10 days, aligning with typical NSAID protocols for acute symptomatic periods.

The clinical profile also addresses population specifics by indicating that use in the pediatric population is not routinely established or recommended due to insufficient data on efficacy and safety. These principles define the procedural boundaries for the drug’s application.

Dolalgial is a pharmaceutical preparation whose active compound is Clonixin Lysinate. Research has been studied for this medication in contexts relevant in trials assessing short-term or episodic symptom patterns, specifically focusing on acute migraine attacks of moderate severity. The most robust research structure, according to official research, involves Randomized Controlled Trials (RCTs). These studies primarily included adult patients, and the key outcomes research examined were measures related to physical discomfort, such as the achievement of a pain-free state and the time it was studied for to see if initial changes in symptoms were observed.

Dolalgial was evaluated in settings involving conditions associated with acute or disruptive episodes, particularly post-procedural pain following minor surgeries, such as dental extractions. The evidence base includes Randomized Controlled Trials (RCTs) that explored how the medicine was observed relative to other comparative treatments included in the study structure. The research documented measurements of discomfort compared to other common Nonsteroidal Anti-inflammatory Drugs or placebo, as well as outcomes related to inflammatory or irritative states, such as swelling.

For broader pain contexts, such as acute renal colic pain and other algic syndromes (muscular or menstrual discomfort), the certainty remains low due to the nature of the available research. Evidence is limited and largely consists of historical data or smaller studies, meaning that sample sizes were modest and a large volume of recent, dedicated, high-quality RCTs is not available. Across all indications, long-term effects are not fully established, and there is a noticeable absence of dedicated studies in older adults or children. The findings describe group patterns, and research does not determine whether an individual will respond similarly outside of the specific conditions under which the trials were conducted.

Common questions about Dolalgial (FAQ)

Q: What specific types of pain is Dolalgial best for?

A: According to the official therapeutic indications, this medicine is used to treat various acute pain syndromes. Regulatory documents specify its use for conditions such as headache, toothache, menstrual pain, and pain following minor surgical procedures or trauma. The medicine is generally used for short-term symptomatic relief.

---

Q: Can Dolalgial help with muscle aches and spasms?

A: Official information indicates that this medicine is used for acute pain associated with algic syndromes, which includes muscular pain and discomfort related to certain soft tissue disorders. Studies have explored its use in these contexts, but official guidance suggests limiting its use to acute, disruptive episodes.

---

Q: Does Dolalgial make you drowsy or sleepy?

A: Official safety documents list potential nervous system effects such as dizziness and headache. For many NSAIDs, somnolence (drowsiness) is documented as a possible but less frequent side effect.

---

Q: Are headaches a common side effect of taking Dolalgial?

A: Headache is a documented adverse reaction affecting the nervous system. According to the drug’s safety profile, these nervous system disturbances are often classified among the common side effects associated with this medication.

---

Q: Can I take Dolalgial on an empty stomach?

A: Official product information suggests taking this medicine with food or milk. This is a common precaution for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and is intended to help minimize the risk of gastrointestinal discomfort or stomach upset.

---

Q: Can teenagers take Dolalgial for menstrual cramps?

A: Official product information states that the use and recommendation for this medicine are primarily established for adult patients. Due to insufficient data on efficacy and safety, its use in the pediatric population, which includes teenagers, is not routinely established or recommended.

---

Q: Is it normal to feel a slight stomach upset after taking Dolalgial?

A: Gastrointestinal disturbances are listed as common side effects. These can include nausea, vomiting, or abdominal pain. Taking the medicine with food may help to reduce this effect.

---

Q: Can Dolalgial affect the results of blood tests?

A: As with many NSAIDs, official precautions advise that clinical tests assessing blood count, kidney function, and liver function should be monitored before and during treatment, particularly for chronic conditions. This is to ensure the medicine is not negatively affecting these parameters.

---

Q: Is Dolalgial addictive or habit-forming?

A: No. Dolalgial, which contains Clonixin Lysinate, is a non-opioid Nonsteroidal Anti-inflammatory Drug (NSAID). As a non-opioid NSAID, the medication is not known to be addictive or habit-forming.

---

Q: Does Dolalgial have any known effects on kidney function?

A: Official safety data indicates that the medicine can affect the renal and urinary system. It is strictly contraindicated in individuals with severe kidney impairment, and caution is advised for patients with pre-existing renal issues.

---

Q: Does taking Dolalgial impact your ability to focus?

A: Nervous system side effects like dizziness and confusion have been reported, according to the official safety profile. These effects may temporarily impact concentration or attention. Patients are advised to be aware of their personal reaction to the medication.

---

Q: Is it safe to drive after taking a dose of Dolalgial?

A: Official product information states that driving or operating machinery should be avoided if side effects such as dizziness or confusion are experienced. This is a standard precaution when a medicine may affect mental alertness.

---

Q: Why is alcohol consumption generally discouraged while on Dolalgial?

A: Regulatory guidance advises avoiding the consumption of alcohol during treatment. This is because combining alcohol with an NSAID can potentially increase the risk and severity of gastrointestinal side effects, such as irritation or bleeding.

---

Q: Does Dolalgial interact with common cold or flu remedies?

A: The medicine is contraindicated (prohibited) for use alongside other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or high-dose salicylates, which are often active ingredients in common cold and flu remedies. This combination is avoided due to an increased risk of adverse effects.

---

Q: Can Dolalgial be used for tension headaches or migraines?

A: Official clinical evidence supports the efficacy of the oral formulation in treating acute migraine attacks of moderate severity. Its use for other types of headaches falls under its general indication for pain syndromes.

---

Q: Why do some forums mention using Dolalgial for nerve pain?

A: Regulatory documents indicate the medicine is used in the treatment of various pain syndromes. While studies focus on nociceptive (pain nerve ending) mechanisms, it is not specifically classified as a treatment for chronic neuropathic pain.

---

Q: Can Dolalgial interact with herbal remedies like St. John's Wort?

A: The drug is known to interact with medicines that increase the risk of gastrointestinal bleeding. Consequently, patient information may include general cautions regarding co-administration with herbal products that could potentially have similar effects.

---

Q: What's the difference between the active ingredients in Dolalgial and aspirin?

A: The active ingredient in Dolalgial is Clonixin Lysinate, which is a fenamate-type NSAID. Aspirin, while also an NSAID, belongs to a different chemical group known as salicylates. Both belong to the same drug class but have distinct chemical structures and profiles.

---

Q: How does Dolalgial affect the liver?

A: The medicine is strictly contraindicated in patients with severe hepatic (liver) failure. Furthermore, regulatory documents advise that clinical tests assessing liver function should be monitored before and during treatment, particularly if the treatment duration is extended.

---

Q: Is there specific patient information or a leaflet available for Dolalgial online?

A: Yes, official patient information leaflets and the Summaries of Product Characteristics (SmPC) are made publicly available by national regulatory agencies. These documents can generally be found on the respective government websites for the country where the medicine is approved.

---

Q: Does body weight influence how effective Dolalgial is?

A: The official protocol establishes a standard dose range for adults. The pharmacological studies that determine appropriate dosing often take factors like body weight into account, as it can influence how the medicine is distributed in the body.

---

Q: Is it true that Dolalgial is a prescription-only medicine?

A: In many regions where it is available, Dolalgial is classified under prescription-only or restricted supply. This classification reflects the need for professional oversight when using a medicine of the Nonsteroidal Anti-inflammatory Drug (NSAID) class.

---

Q: If I have a history of ulcers, is Dolalgial still an option?

A: Official safety information strictly states that the medicine is contraindicated in patients with active or recurrent gastrointestinal bleeding. Due to the known risk of gastrointestinal ulceration, a history of these conditions is a major consideration for use.

---

Q: Can Dolalgial be used to reduce fever?

A: Yes, as an NSAID, the medicine possesses established antipyretic (fever-reducing) actions. This effect works by modifying the body’s thermal set-point through its pharmacological mechanism of action.

---

Q: What evidence supports the use of Dolalgial for chronic conditions?

A: Official regulatory guidance dictates that the medicine’s duration of therapy is constrained to a short-term course, typically lasting around 7 to 10 days, for acute symptoms. Evidence for its safety and efficacy in long-term treatment of chronic conditions is not fully established.

---

Q: Does Dolalgial cause fluid retention or swelling?

A: Fluid retention and effects on the renal and urinary system are documented adverse reactions. As with many NSAIDs, official documents indicate this medicine may cause or contribute to swelling (edema) in some patients.

---

Q: How is Dolalgial typically eliminated from the body?

A: According to official pharmacokinetic data, the active substance is primarily eliminated from the body through the renal system (kidneys). This is why patients with kidney impairment may require special dose considerations.

---

Q: Are there any known issues with abruptly stopping Dolalgial after long-term use?

A: Regulatory guidance strictly limits the duration of therapy to a short-term course. Because of this intended short-term use, issues related to abruptly stopping after extended use are not typically documented in the safety profile.

---

Q: Do studies show Dolalgial is effective for inflammatory conditions?

A: Yes, the medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) precisely because of its established anti-inflammatory properties. Its mechanism of action works by blocking the synthesis of key chemical mediators that drive inflammation in the body.

How to Store and Dispose of Dolalgial

The storage and handling of Dolalgial (Clonixin Lysinate) film-coated tablets must comply with official regulatory documentation to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Maximum Temperature	Do not store the medicine above mathbf30 C.
Container and Protection	Keep in the original container to protect it from moisture.
Stability Limit	Do not use the product after the expiration date (CAD) marked on the packaging.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Official disposal guidelines prohibit discarding the medicine through drains or in the household trash. Unused or expired Dolalgial and its containers must be taken to a designated pharmaceutical waste collection point (such as a SIGRE Point) for proper environmental handling.